Myeloid-derived suppressor cells as therapeutic target in hematological malignancies
about
Bone Marrow Immunity and MyelodysplasiaNovel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myelomaElutriated lymphocytes for manufacturing chimeric antigen receptor T cells.Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.Applying Precision Medicine and Immunotherapy Advances from Oncology to Host-Directed Therapies for Infectious DiseasesMyeloid derived suppressor cells in chronic myeloid leukemia.Prognostic Value of CD11b Expression Level for Acute Myeloid Leukemia Patients: A Meta-AnalysisMultiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells.The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib.Microenvironment abnormalities and lymphomagenesis: Immunological aspects.The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells.New approaches for the immunotherapy of acute myeloid leukemia.Myeloid-derived suppressor cells in B cell malignancies.Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer.Immune checkpoint pathways: perspectives on myeloid malignancies.Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression.IL-12, IL-15, and IL-18 pre-activated NK cells target resistant T cell acute lymphoblastic leukemia and delay leukemia development in vivo.Challenges in vaccine therapy in hematological malignancies and strategies to overcome them.Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities.Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms.17β-Oestradiol enhances the expansion and activation of myeloid-derived suppressor cells via signal transducer and activator of transcription (STAT)-3 signalling in human pregnancy.Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function.Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow.Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!B cell lymphoma progression promotes the accumulation of circulating Ly6Clo monocytes with immunosuppressive activity.Novel adherent CD11b+ Gr-1+ tumor-infiltrating cells initiate an immunosuppressive tumor microenvironment.
P2860
Q26739239-18EA5491-E5A0-4019-AFEF-61CC90C275EBQ26770391-9F421511-61B8-4311-9C88-67D0D3062CD1Q28077635-7394727F-BA04-42CA-9453-D6A5CAD91302Q30252944-9EE3333A-AECD-4B9C-8452-93F3BEFE0A99Q33593877-A9930E2F-F1F2-4A45-AF5C-32AC9F532F64Q33849778-4FAF470C-5E65-4336-BA91-BA7FCC78D8D6Q35609094-4F0E5568-3D64-4B15-8DEE-56C696E04775Q35756199-FCF5151F-819B-4EAD-81CE-15D9E108A749Q35833055-E33C04EE-E74F-4370-9A14-B0799953B427Q35898395-80CB9CB3-038B-4461-A0A7-FC2D9240666DQ36118020-36D8E59A-B4DA-45DB-AA21-798EE6105EFAQ36685551-2EB7BCE4-327F-4F6F-AA50-CE095D7554EDQ36982805-5121BA2C-2E00-45A9-BFBF-71C7F2842BFFQ38482206-F8FB0A19-836F-498A-AA23-4259652CBA83Q38578686-3DAC4D83-DB85-4D13-B6DD-B412E8D4AB06Q38708402-CB37269E-D9BF-44C6-BB75-529EB040CEC6Q38741840-0A203024-7C51-4F95-ABB7-7759EEF7B56CQ38750608-CFECCFCE-CF52-47D7-9E2F-02B6D7669FD8Q38787818-BFBEF198-367B-43BB-AE84-0CE7642E26CAQ38839145-E7DEFC3A-E6A1-4FF3-986D-A7FE0464D0C3Q38843235-D7E90A98-F257-4F9F-B679-A72CD2B18DDFQ38953721-D213F94C-9D13-4FEA-9B3D-0E92F0F18150Q39072004-5B8F145E-39FB-4446-AE51-7F4EA9CC9ED1Q39335524-D6F080B2-6EF2-4A30-8F16-CF05B2422E4EQ39896275-7C3E0164-2B95-472E-824E-56D9624FE02FQ39928926-C31D10DC-B9BB-4F0A-AA4E-F7C2D693341EQ47229822-93EDF620-DF07-4716-BC15-91F175A48CDBQ47289766-B866F488-4F0C-4FD7-B1F4-8D860040ACFFQ50545382-DF6864E3-9790-442C-94E9-30E4003B9B70Q52655046-ED007F2F-0C67-44DC-9650-5BFB2B4D4164
P2860
Myeloid-derived suppressor cells as therapeutic target in hematological malignancies
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Myeloid-derived suppressor cells as therapeutic target in hematological malignancies
@ast
Myeloid-derived suppressor cells as therapeutic target in hematological malignancies
@en
Myeloid-derived suppressor cells as therapeutic target in hematological malignancies
@nl
type
label
Myeloid-derived suppressor cells as therapeutic target in hematological malignancies
@ast
Myeloid-derived suppressor cells as therapeutic target in hematological malignancies
@en
Myeloid-derived suppressor cells as therapeutic target in hematological malignancies
@nl
prefLabel
Myeloid-derived suppressor cells as therapeutic target in hematological malignancies
@ast
Myeloid-derived suppressor cells as therapeutic target in hematological malignancies
@en
Myeloid-derived suppressor cells as therapeutic target in hematological malignancies
@nl
P2093
P2860
P50
P3181
P356
P1476
Myeloid-derived suppressor cells as therapeutic target in hematological malignancies
@en
P2093
Els Van Valckenborgh
Ivan Van Riet
Jo A Van Ginderachter
Karin Vanderkerken
Qods Lahmar
Xenia Geeraerts
P2860
P3181
P356
10.3389/FONC.2014.00349
P407
P577
2014-12-08T00:00:00Z